Repurposing Approved Drugs: New Strategies for Cancer Therapy

Introduction to Drug Repurposing in Cancer Therapy

Understanding Drug Repurposing in Oncology

Drug repurposing is the strategic use of existing drugs approved by the FDA for new therapeutic applications, notably in cancer treatment. Instead of developing new medications from scratch, this approach leverages drugs with established safety profiles to target cancer cells or improve patient outcomes.

Why Drug Repurposing Matters

One major advantage of repurposing FDA-approved drugs is the accelerated timeline and reduced cost associated with bringing treatments to patients. Since these drugs have undergone rigorous safety evaluation, their transition into oncology can be smoother and more efficient compared to novel drug development.

Responding to Cancer's Challenges

Cancer is a complex and heterogeneous disease that is often resistant to standard therapies. With growing rates of cancer and persistent unmet medical needs, repurposed drugs offer promising opportunities to enhance treatment efficacy, reduce toxicity, and personalize therapy.

Many approved drugs originally designed for conditions like diabetes, inflammation, or infections, such as Metformin and Thalidomide, have demonstrated anticancer properties. Their ability to modulate cancer metabolism, immune responses, and signaling pathways is being actively explored in clinical trials.

This evolving landscape highlights drug repurposing as a vital complement to innovative cancer treatments, expanding options for patients worldwide.

Evolution of Cancer Treatment Over the Last Decade

How has cancer treatment improved in the last 10 years?

Over the past decade, cancer treatment has undergone significant transformation, largely due to breakthroughs in immunotherapy, targeted therapy, and precision medicine. These innovations have shifted treatment from a one-size-fits-all approach to more personalized strategies tailored to individual tumor genetics and patient profiles.

Improvements in Immunotherapy, Targeted Therapy, and Precision Medicine

Immunotherapies such as CAR T-cell therapy and immune checkpoint inhibitors have revolutionized how the immune system can be harnessed to attack cancer cells. Targeted therapies, including drugs that specifically inhibit mutated proteins like KRAS, have provided new options for patients with previously undruggable cancers. Precision medicine has been empowered by molecular diagnostic tools such as advanced genetic profiling, facilitating personalized treatment plans that improve survival rates and reduce toxic side effects.

Role of AI and Molecular Diagnostics in Personalized Treatment

Artificial intelligence (AI) technologies now analyze vast datasets from imaging, tissue samples, and blood biomarkers to enhance early detection and classification of cancers. By identifying molecular and genetic alterations unique to each tumor, AI-driven diagnostics enable more accurate treatment selection, accelerating the development of specialized therapies. For more details, see AI-based diagnostics in the US.

Advances in Surgical, Radiation Techniques, and Prevention

Surgical innovations using fluorescent dyes and targeted radiotherapies improve tumor removal accuracy while minimizing damage to healthy tissue. Radiation therapy has become more precise, reducing side effects and improving post-treatment recovery. Complementary to these advances, robust prevention efforts—like improved cancer screening protocols and lifestyle interventions such as smoking cessation and weight management—contribute significantly to lowering cancer incidence and mortality.

Collectively, these strides are reshaping cancer care, offering enhanced hope, better quality of life, and prolonged survival for patients worldwide.

Innovative Therapies and Breakthroughs in Oncology

What are the latest innovations and breakthroughs in cancer treatment?

Cancer treatment has rapidly evolved with several groundbreaking advances delivering more precise and effective therapies. One major leap is the FDA approval of KRAS inhibitors like sotorasib and adagrasib, which target mutated KRAS proteins responsible for about 25% of cancers—including lung, colorectal, and pancreatic cancers. These drugs address a previously ‘undruggable’ mutation and represent a milestone in targeted therapy (KRAS gene mutations in cancer).

Immuno-oncology is also making strides by combining immune checkpoint inhibitors with PARP inhibitors or novel vaccines designed to target specific tumor mutations. These combination approaches enhance immune system responses and are showing promising results in prolonging survival and preventing cancer recurrence (AI technology in cancer detection).

Emerging cell therapies are expanding beyond CAR-T cells to include CAR natural killer (CAR NK) cells. These innovative immune cells offer a potential for improved cancer cell targeting with possibly reduced side effects, broadening the arsenal of adoptive cell therapies (tumor treatment strategies).

On the diagnostic and delivery front, advanced technologies like DZ-002 fluorescent dye conjugate therapy are being developed to precisely detect and treat tumors. This targeted radiation therapy improves tumor visualization and drug delivery, especially beneficial in difficult-to-treat cancers such as pancreatic cancer (Breakthrough cancer therapy).

Together, these innovations form a new era in oncology, combining precise molecular targeting, immunomodulation, novel cellular therapies, and cutting-edge diagnostic tools to improve outcomes and quality of life for cancer patients.

The Science Behind Drug Repurposing in Cancer Therapy

What is drug repurposing in cancer treatment and how does it work?

Drug repurposing in cancer treatment30610-0/fulltext) involves using already FDA-approved drugs that were originally designed for other diseases to target cancer cells. This approach speeds up the availability of new cancer therapies since these drugs have known safety records and can be tested more quickly than new drugs. Many repurposed drugs are able to inhibit tumor growth, promote cancer cell death, or modify the tumor environment to make treatments more effective.

Examples of repurposed drugs and their anti-cancer mechanisms

Several widely used medications show promising results against cancer. For example:

• Metformin, a drug for type 2 diabetes, activates AMPK, reprograms cancer cell metabolism, and inhibits tumor growth, improving survival rates in cancers like non-small cell lung and colorectal cancers (Repurposing approved drugs for cancer therapy, Repurposing chronically used drugs in cancer therapy).
• Thalidomide, initially used for inflammation, helps treat multiple myeloma and lymphoma by modulating immune responses and reducing inflammatory cytokines (Thalidomide and derivatives for multiple myeloma, Immunomodulatory effects of thalidomide).
• Propranolol, an anti-hypertensive beta blocker, impedes tumor progression by inhibiting angiogenesis and pro-survival signaling (Repurposing chronically used drugs in cancer therapy.
• Statins may directly kill cancer cells and boost immune responses, showing potential in head and neck malignancies (Statins and cancer therapy, Statins for head and neck cancer survival).

Other repurposed candidates include proteasome inhibitors and anti-inflammatory drugs, being trialed for their abilities to control drug resistance and reduce treatment toxicity (Proteasome inhibitors in multiple myeloma, Anti-inflammatory drugs in cancer care.

Role of clinical trials and institutions like Emory University

Clinical studies are critical to validate the anti-cancer effects of repurposed drugs. Institutions such as Emory University’s Winship Cancer Institute actively conduct trials to assess how these drugs can improve immunotherapy outcomes, prevent recurrence, or enhance chemotherapy. Their research includes exploring combinations and determining optimal timing to maximize benefits. Ongoing trials also help establish the best dosages and safety for cancer-specific applications.

Significance for difficult cancers like pancreatic cancer

Hard-to-treat cancers such as pancreatic cancer desperately need innovative therapies. Drug repurposing offers promising new options by leveraging drugs like metformin and novel targeted agents to improve outcomes (Drug repurposing in cancer treatment). For example, targeted radiation therapies enhanced by repurposed compounds are advancing through phase 2 trials aiming to extend survival and quality of life in pancreatic cancer patients (Breakthrough cancer therapy. This approach helps address the unmet medical needs in these aggressive cancers by providing affordable, accessible treatment alternatives faster than traditional drug development.

Highlighted Examples of Successfully Repurposed Cancer Drugs

Which drugs have been successfully repurposed for cancer treatment?

Several drugs originally developed for non-cancer conditions have found new life as cancer therapies. Thalidomide and derivatives for multiple myeloma is a striking example; although it was once used for morning sickness, it is now a cornerstone treatment for multiple myeloma and related hematological cancers. This transformation highlights the potential for drugs with known safety profiles to be redirected against tumors.

How has Metformin contributed to cancer therapy?

Metformin in cancer treatment, widely used since 1995 to treat type 2 diabetes, exhibits significant anticancer activities. Through the AMPK activation by Metformin, metformin reprograms cancer cell metabolism and induces cell cycle arrest, promoting apoptosis. Clinical studies have shown improvements in progression-free and overall survival in cancers such as non-small cell lung cancer, especially in patients harboring KRAS gene mutations in cancer.

What are some emerging repurposed drug candidates?

Other promising candidates include Disulfiram and nelfinavir in cancer trials, originally an alcoholism drug, which targets oxidative stress pathways in cancer cells. Statins and cancer therapy, typically used for cholesterol control, may enhance survival rates in head and neck cancers by modulating the immune response and directly affecting tumor cells. Beta blockers like propranolol are being explored for their antiangiogenic and anti-inflammatory effects in multiple cancer types, including breast and pancreatic cancers (Repurposing chronically used drugs in cancer therapy. Additionally, antifungal agents such as sulconazole show immunomodulatory potential by inhibiting immune checkpoints like PD-1 (Drug repurposing in cancer therapy.

What benefits do repurposed drugs offer in cancer treatment?

Repurposed drugs can enhance treatment outcomes by adding Cytostatic activity of approved drugs or helping control treatment-related side effects. For example, certain repurposed anti-inflammatory agents reduce chemotherapy toxicity, while others, such as Proteasome inhibitors in multiple myeloma, improve therapy effectiveness against resistant tumors. This dual role elevates patient quality of life and broadens therapeutic options without the lengthy development times associated with new drugs (Repurposing approved drugs for cancer therapy).

---

Drug	Original Use	Repurposed Cancer Use
Thalidomide	Morning sickness	Multiple myeloma, lymphoma
Metformin	Type 2 diabetes	Lung, colorectal, breast cancers
Disulfiram	Alcoholism	Oxidative stress pathway modulation
Statins	Cholesterol management	Survival improvement in head and neck
Beta blockers	Hypertension	Antiangiogenesis, anti-inflammatory
Sulconazole	Antifungal	Immune checkpoint inhibition (PD-1)

This expanding repertoire of repurposed medicines leverages existing pharmacology and clinical experience to innovate cancer care rapidly and cost-effectively.

Repurposed Drugs Targeting Common Cancers: Breast, Colon, and Lung

What are some examples of repurposed drugs used specifically for breast, colon, and lung cancer?

Several non-cancer drugs have demonstrated potential in treating breast, colon, and lung cancers through the strategy of Drug repurposing in cancer treatment.

Metformin’s efficacy in lung and colon cancers

Metformin, widely used for type 2 diabetes, has shown promising anticancer effects, particularly in lung and colon cancers. It activates AMPK activation by Metformin and inhibits mTOR signaling, which suppresses tumor growth. Clinical studies report that metformin use is associated with improved progression-free and overall survival in non-small cell lung cancer patients, especially those with KRAS mutations in cancer. Additionally, metformin reduces the risk of colorectal cancer through mechanisms like cell cycle arrest and reduced insulin levels (Repurposing chronically used drugs in cancer therapy, Metformin in cancer treatment.

Anti-inflammatory agents like aspirin and COX-2 inhibitors for colon cancer prevention

Aspirin and COX-2 inhibitors, known Anti-inflammatory drugs in cancer care, are under investigation for their role in colon cancer prevention. These agents help reduce inflammation and may enhance chemosensitivity, thus potentially lowering cancer risk and suppressing tumor progression. Large-scale clinical trials continue to explore their efficacy and safety in this context (Repurposing FDA-approved drugs for cancer, Drug repurposing in cancer therapy).

Investigational drugs such as prochlorperazine for HER2-positive breast cancer

Prochlorperazine, an anti-emetic and antipsychotic drug, is an example of a repurposed drug being studied for breast cancer. It is being tested as part of combination treatments targeting HER2-positive metastatic breast cancer, aiming to improve therapeutic outcomes by modulating cancer cell growth and the tumor microenvironment (Drug repurposing in cancer therapy30610-0/fulltext)).

Overview of ongoing clinical investigations

Numerous clinical trials are actively evaluating repurposed drugs for these common cancers. Metformin and aspirin feature prominently, with ongoing studies assessing their impact on cancer recurrence and survival. Other candidates like beta blockers, statins, and psychotropic medications are also being tested, often combined with standard therapies to reduce side effects or overcome resistance (Repurposing FDA-approved drugs for cancer, Repurposing approved drugs for cancer therapy.

This growing research highlights the potential to improve cancer care by leveraging existing, well-characterized drugs. However, while the promise is significant, these treatments still require rigorous clinical validation before becoming standard care options.

Strategies Targeting Cancer Stem Cells with Repurposed Drugs

What role do cancer stem cells (CSCs) play in therapy resistance and relapse?

Cancer stem cells are a small but critical subset of tumor cells responsible for driving cancer progression, metastasis, and resistance to treatments. These cells possess self-renewal and differentiation capabilities that allow tumors to regenerate after initial therapy, causing relapse and treatment failure. CSCs evade conventional chemotherapy and radiotherapy because these therapies primarily target the bulk of tumor cells, often sparing CSCs. For more details, see Cancer stem cells role.

Which signaling pathways and surface markers are linked to CSCs?

CSCs are characterized by specific surface markers such as CD44, CD24, CD133, EpCAM, and others, which vary depending on the cancer type. Important pathways regulating CSC self-renewal and survival include the Wnt/β-catenin, Notch, Hedgehog (Hh), and TGF-β signaling pathways. Additionally, the tumor microenvironment and hypoxia-inducible factors help maintain CSC stemness and contribute to drug resistance. These signaling routes present attractive targets to eradicate CSCs and overcome tumor relapse. Further information can be found at Targeting cancer stem cells.

What repurposed drugs target CSCs and how?

Several non-cancer drugs originally approved for other indications show promise in targeting CSCs. Aspirin and metformin disrupt CSC pathways by modulating signaling cascades such as AMPK activation and inhibition of pro-survival signals, leading to reduced proliferation and induced apoptosis. Anti-psychotic drugs, currently under investigation, are believed to affect drug-resistant CSC phenotypes by interfering with cellular signaling and metabolic pathways. These repurposed drugs offer a faster and more cost-effective route to novel cancer therapies since their safety profiles and pharmacodynamics are well understood. See Repurposing FDA-approved drugs for cancer and Drug repurposing in cancer therapy for more insights.

How are micronutrients and combination treatments integrated to improve tumor control?

Micronutrients like vitamins A (e.g., all-trans retinoic acid), C, D, curcumin, and phytochemicals such as sulforaphane have demonstrated anti-cancer effects, including disrupting CSC-related pathways. Combining repurposed drugs with these natural compounds and conventional chemo- or radiotherapy is being explored to target both bulk tumor cells and CSCs simultaneously. Such combination therapies aim to overcome chemoresistance, reduce tumor recurrence, and improve overall treatment outcomes. Relevant research is available at Cancer stem cells and cancer progression and Nanomedicine in cancer treatment.

What newer strategies are being researched to treat cancer, and what challenges do they face?

Emerging cancer treatments focus on precision medicine approaches, including small-molecule kinase inhibitors, antibody-drug conjugates, and cell-based therapies like CAR-T and CAR-NK cells. Gene editing techniques such as CRISPR are in trials, aiming to correct or disrupt cancer-causing mutations. Oncolytic viruses and nanomedicine delivery systems enhance tumor targeting and reduce toxicity. However, challenges include drug resistance, managing side effects, the high cost of development, and ensuring broad patient access. Multi-omics and AI are being leveraged for better personalized therapies, but tumor complexity and clinical implementation hurdles remain significant. For more information, see tumor treatment strategies and AI technology in cancer detection.

Advanced Drug Delivery and Nanomedicine Supporting Repurposed Agents

How are nanoparticles, liposomes, and polymeric systems used for targeted drug delivery in cancer therapy?

Nanomedicine in cancer treatment employs biocompatible carriers such as nanoparticles, liposomes in cancer drug delivery, micelles, and polymeric systems to enhance the delivery of cancer drugs. These advanced delivery systems improve drug bioavailability, protect therapeutic agents from degradation, and facilitate controlled drug release. By functionalizing nanoparticles with targeting ligands—such as antibodies or peptides—drugs can specifically home in on tumor cells, sparing healthy tissue and reducing side effects. For example, Abraxane, a nanoparticle albumin-bound formulation of paclitaxel, is already approved for treating pancreatic ductal adenocarcinoma (PDAC), illustrating how these systems improve treatment outcomes.

What applications do nanomedicine and advanced delivery systems have in pancreatic and other cancers?

Nanomedicine in cancer treatment shows particular promise in hard-to-treat cancers like pancreatic cancer. Abraxane enhances chemotherapy effectiveness in PDAC through improved tumor penetration. Additionally, nanoparticles engineered to target overexpressed receptors on cancer cells, such as HER2 or EGFR, allow precision delivery of repurposed drugs directly to tumor sites in breast, lung, and colorectal cancers.

What is the role of extracellular vesicles and exosomes in cancer diagnosis and therapy?

Extracellular vesicles (EVs), especially exosomes, participate actively in cancer progression and metastasis by facilitating cell-to-cell communication. They serve as emerging diagnostic biomarkers; for instance, GPC1-positive exosomes have been used to detect pancreatic cancer in clinical trials. Therapeutically, exosomes are being engineered as natural drug delivery vehicles, offering targeted transfer of repurposed anticancer agents and potentially overcoming resistance mechanisms. For detailed insights, see Nanomedicine in cancer treatment.

What are the advantages and challenges of nanomedicine in oncology?

Nanomedicine offers significant benefits, including enhanced drug targeting specificity, reduced systemic toxicity, and improved pharmacokinetics. However, challenges remain, such as manufacturing scalability, potential nanoparticle-induced toxicity, and the complexity of fully characterizing interactions within the tumor microenvironment. Continued research and clinical evaluation are essential to optimize these nanocarriers for repurposed drugs, aiming to maximize efficacy and patient safety while overcoming cancer’s heterogeneity.

Aspect	Description	Example/Application
Nanoparticles & Liposomes	Enhance delivery, bioavailability, controlled release	Abraxane for pancreatic cancer
Targeting Ligands	Improve tumor specificity	Antibodies targeting HER2 (Nanomedicine in cancer treatment)
Extracellular Vesicles	Biomarkers and drug delivery vehicles	GPC1-positive exosomes for pancreatic cancer (Nanomedicine in cancer treatment
Challenges	Toxicity, manufacturing, tumor microenvironment interaction	Ongoing in clinical research (Nanomedicine in cancer treatment

Immunotherapy and Drug Repurposing Synergies

How does the immunotherapy drug pembrolizumab work to treat certain cancers?

Pembrolizumab is a monoclonal antibody that targets the PD-1 receptor on immune cells, acting as a checkpoint inhibitor. Normally, when PD-1 binds PD-L1 on cancer cells, it suppresses the immune system's ability to attack tumors. Pembrolizumab blocks this interaction, reactivating T-cells to recognize and destroy cancer cells effectively. Approved for cancers such as melanoma, non-small cell lung cancer, and Hodgkin lymphoma, it is administered intravenously and represents a breakthrough in enabling the immune system to combat tumors more efficiently. While highly effective, close monitoring is needed due to potential immune-related side effects.

How do repurposed drugs enhance immunotherapy efficacy?

Repurposed drugs like beta blockers and statins are showing promise in boosting immunotherapy outcomes. Beta blockers, for instance, may reduce inflammation in the tumor microenvironment, increasing the sensitivity of cancers such as multiple myeloma to immunotherapeutic agents. Statins have demonstrated the ability to improve survival and immune response in head and neck cancers, possibly by directly affecting cancer cells and enhancing immune function. These non-cancer medications, with established safety profiles, offer affordable and effective avenues to augment existing immunotherapies (Drug repurposing in cancer treatment.

What ongoing trials explore combinations of immunotherapy with repurposed agents?

Multiple clinical trials are underway investigating the combination of immunotherapies like pembrolizumab with repurposed drugs. Institutions such as the Winship Cancer Institute are leading efforts to test beta blockers, statins, and other common medications alongside checkpoint inhibitors. These trials aim to evaluate improvements in tumor control, reduction in recurrence, and amplification of immune system responses. Early studies suggest that such combinations may also limit toxicities and overcome resistance, paving the way for more personalized and effective cancer regimens (Repurposing FDA-approved drugs for cancer.

How might combining immunotherapy and repurposed drugs improve immune responses and tumor control?

The synergy from combining immunotherapy with repurposed drugs has the potential to enhance the immune system’s ability to fight cancer cells and address tumor heterogeneity. By modulating inflammation, cytokine activity, and the tumor microenvironment, these drug combinations may strengthen T-cell activation and persistence. Furthermore, they can target cancer stem cells and resistant tumor populations often unaffected by traditional treatments. This integrated approach strives for durable responses, reduced relapse rates, and improved patient outcomes in various hard-to-treat malignancies (Cancer stem cells and drug repurposing).

Regulatory and Research Frameworks Facilitating Drug Repurposing

What systematic approaches support drug repurposing in oncology?

Computational methods such as bioinformatics, systems pharmacology, and machine learning play a vital role in identifying candidates for drug repurposing. These approaches offer a more reliable and targeted way to screen existing drugs compared to serendipitous discoveries, enabling mechanism-based repositioning efforts.

How do multidisciplinary networks accelerate clinical validation?

Collaborative infrastructures like the University College London ([UCL] Repurposing Therapeutic Innovation Network (TIN)](https://www.sciencedirect.com/science/article/pii/S1359644625001035) foster multidisciplinary partnerships among academia, industry, and patient groups. These networks support the entire pipeline from hypothesis generation to regulatory approval, expediting translational research and clinical development of repurposed drugs.

What funding mechanisms and regulatory incentives facilitate repurposing?

Incentives such as orphan drug designations, clinical investigation exclusivity, and targeted funding initiatives boost the commercial viability of repurposed therapies. Financial support addresses the often costly clinical trials and development phases, encouraging pharmaceutical companies and academic institutions to invest in repurposing projects.

What are the major challenges in clinical trials and dose optimization?

Repurposing requires rigorous preclinical and clinical validation to ascertain efficacy and safety in the new indication. Dose optimization and understanding pharmacokinetics and pharmacodynamics in cancer contexts are crucial since drug behavior may differ from the original use. These challenges often contribute to regulatory complexity and necessitate careful trial design.

Aspect	Description	Impact on Drug Repurposing
Computational Methods	Bioinformatics and machine learning	More precise candidate selection
Multidisciplinary Networks	Collaboration across sectors	Accelerated development and approval
Regulatory Incentives	Orphan designation, exclusivity	Enhanced commercial feasibility
Clinical Trial Complexity	Need for dose, safety, efficacy studies	Lengthier validation, higher costs

These regulatory and research frameworks significantly shape the evolving landscape of drug repurposing in cancer therapy by balancing speed, safety, and innovation.

Future Outlook: Integration of Repurposing in Personalized Cancer Care

Clinical Trial Trends at Leading Cancer Centers

The future of cancer treatment is increasingly shaped by drug repurposing initiatives spearheaded by institutions like the Winship Cancer Institute of Emory University and Memorial Sloan Kettering (MSK). Winship leads multiple clinical trials exploring repurposed drugs, such as statins and beta blockers, aiming to enhance immunotherapy responses and prevent cancer recurrence. Similarly, MSK has pioneered phase 1 and 3 trials examining novel combinations of repurposed and targeted therapies, including innovative KRAS inhibitors and vaccines, to improve patient outcomes (Top Cancer Treatment Advances at MSK in 2025).

Emphasis on Combination Therapies and Prevention

An important trend in cancer care involves combination therapies that pair repurposed drugs with conventional treatments, aiming to overcome resistance and reduce toxicity. Efforts at improving the prevention of cancer recurrence, especially through post-surgical immunotherapy, are being actively studied. Enhancing immunotherapy efficacy using repurposed drugs, such as checkpoint blockade agents combined with NSAIDs or metabolic modulators, shows promise in producing durable tumor suppression (Repurposing FDA-approved drugs for cancer.

The Role of AI and Multi-Omics in Precision Medicine

Artificial intelligence (AI) and multi-omics technologies are revolutionizing personalized oncology. AI aids in precise tumor profiling and analyzing genomic, proteomic, and metabolomic data to tailor repurposed drug regimens to individual tumor characteristics. This integrative approach allows clinicians to optimize therapy, improving progression-free survival and reducing adverse effects by predicting the most effective drug combinations (AI technology in cancer detection, tumor treatment strategies.

Impact on Cost, Accessibility, and Patient Quality of Life

Repurposed drugs, often inexpensive with established safety records, offer a more cost-effective alternative to new drug development, potentially improving broad accessibility. By reducing chemotherapy toxicities and enhancing targeted treatments, repurposing can enhance patient quality of life. Furthermore, the availability of generic formulations accelerates clinical adoption, making cutting-edge therapies feasible for diverse populations (Drug repurposing in cancer therapy.

Together, these innovations position drug repurposing as a critical component of next-generation personalized cancer care, promising improved outcomes and expanded treatment possibilities.

Concluding Perspectives on Repurposed Drugs Transforming Cancer Therapy

Accelerating Innovation in Cancer Treatment

Repurposed drugs offer a valuable avenue for cancer therapy by leveraging existing medications with known safety profiles. These drugs, like metformin and thalidomide, have demonstrated promising cytostatic and immunomodulatory effects across various cancers. Their cost-effectiveness and established clinical data shorten development timelines, enabling quicker patient access to potentially life-saving treatments.

Collaborative and Multidisciplinary Approaches

The success of drug repurposing hinges on strong collaboration among academic institutions, industry partners, and regulatory agencies. Networks such as the UCL Therapeutic Innovation Network foster multidisciplinary efforts to streamline research from preclinical studies to clinical trials. Combining repurposed drugs with modern therapies enhances efficacy while reducing toxicity, exemplifying innovation in personalized oncology care.

The Road Ahead: Rigorous Validation and Patient-Centered Progress

Ongoing and future clinical trials are essential to validate the safety and therapeutic benefits of repurposed drugs rigorously. Randomized studies remain the gold standard to establish efficacy and optimize dosage regimens. Emphasizing patient access to affordable, innovative therapies will ensure these advancements translate into improved survival and quality of life for cancer patients worldwide.